Literature DB >> 2784748

Immunohistochemical analysis of contact sensitivity reactions in the guinea-pig using novel monoclonal antibodies: the influence of topical cyclosporin A.

S N Payne1, A W Thomson.   

Abstract

When applied topically to guinea-pig skin from the time of epicutaneous antigen challenge, cyclosporin A (CsA) in ethanol:olive oil (1:2) significantly reduced contact sensitivity reactions to dinitrofluorobenzene (DNFB). This immunosuppressive effect was no longer apparent when initial drug administration was delayed for several hours, or when a non-immunosuppressive cyclosporin derivative was applied. Attenuation of skin reactions was accompanied by significant reductions in T cells recognized by putative pan T cell (CT7) and T cytotoxic/suppressor cell (CT6) monoclonal antibodies, whilst there were also concomitant decreases in basophil infiltration. There was no reduction in epidermal Langerhans cells or in infiltrating mononuclear cells recognized by MSGp9 (mainly dendritic cells) in CsA-treated reaction sites. There was no apparent reduction in Ia antigen expression (staining with MSGp8) on intralesional inflammatory cells with CsA treatment. Whilst demonstrating the efficacy of topical CsA in contact sensitivity, our findings suggest that more than one mechanism may be operative in the suppression of these cutaneous inflammatory reactions.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2784748      PMCID: PMC1541955     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  27 in total

1.  Detection of cell surface antigens in cryostat sections with immunogold-silver staining.

Authors:  M De Waele; J De Mey; P Reynaert; M F Dehou; W Gepts; B Van Camp
Journal:  Am J Clin Pathol       Date:  1986-05       Impact factor: 2.493

2.  Quantitative studies on the Langerhans cell population of guinea pig epidermis.

Authors:  K Wolff; R K Winkelmann
Journal:  J Invest Dermatol       Date:  1967-06       Impact factor: 8.551

3.  Placebo-controlled trial of topical cyclosporin in severe alopecia areata.

Authors:  Y de Prost; D Teillac; F Paquez; L Carrugi; H Bachelez; R Touraine
Journal:  Lancet       Date:  1986-10-04       Impact factor: 79.321

4.  Suppression of the allergic contact reaction in the guinea pig by cyclosporin A.

Authors:  C Anderson; O Groth
Journal:  Int Arch Allergy Appl Immunol       Date:  1985

5.  Production of monoclonal antibodies defining guinea pig T-cell surface markers and a strain 13 Ia-like antigen: the value of immunohistological screening.

Authors:  B T Tan; F Ekelaar; J Luirink; G Rimmelzwaan; A J De Jonge; R J Scheper
Journal:  Hybridoma       Date:  1985

6.  The prolongation of skin allograft survival by topical use of cyclosporine A.

Authors:  X F Zhao; T J Schroeder; J W Alexander; P Miskell; S J Gonce; G F Babcock
Journal:  Transplant Proc       Date:  1988-04       Impact factor: 1.066

7.  Perturbation of epidermal Langerhans cells in immunosuppressed human renal allograft recipients.

Authors:  R D Sontheimer; P R Bergstresser; P Gailiunas; J H Helderman; J N Gilliam
Journal:  Transplantation       Date:  1984-02       Impact factor: 4.939

8.  Immunocytochemical identification and quantitation of mononuclear cells in the meninges during the development of chronic relapsing experimental allergic encephalomyelitis (CREAE) in the guinea pig.

Authors:  A V Antoniou; D Parker; J L Turk; B T Tan; R J Scheper
Journal:  Cell Immunol       Date:  1986-02       Impact factor: 4.868

9.  Induction and regulation of contact hypersensitivity by resident, bone marrow-derived, dendritic epidermal cells: Langerhans cells and Thy-1+ epidermal cells.

Authors:  S Sullivan; P R Bergstresser; R E Tigelaar; J W Streilein
Journal:  J Immunol       Date:  1986-10-15       Impact factor: 5.422

10.  Cutaneous basophil hypersensitivity. II. A light and electron microscopic description.

Authors:  H F Dvorak; A M Dvorak; B A Simpson; H B Richerson; S Leskowitz; M J Karnovsky
Journal:  J Exp Med       Date:  1970-09-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.